Abstract
The inflammation of the brain's parenchyma is known as encephalitis. The main culprits are arboviruses, varicella-zoster virus, and herpes simplex virus. Despite being a chronic consequence of encephalitis, post-encephalitic parkinsonism (PEP) often manifests as a febrile illness with neurological dysfunction. Since then, PEP, a secondary parkinsonian syndrome, has been linked to autoimmune, bacterial, and viral origins.
This study examines the etiological, clinical, and neuropathological differences between PEP and idiopathic Parkinson's disease (PD). PEP differs from Parkinson's disease in that it is defined by extensive tau pathology rather than α-synuclein aggregates (Lewy bodies), lacks considerable iron buildup, and often affects younger individuals with unusual symptoms such as ocular palsy and oculogyric crises. Instead of direct viral damage, pathogenesis is assumed to be caused by autoimmune processes such as molecular mimicry and bystander activation.
Due to its latency period between encephalitis and the onset of symptoms, as well as its overlapping symptoms with Parkinson's disease, PEP is currently difficult to diagnose. Neuroimaging frequently shows basal ganglia and brainstem hyperintensities to differentiate PEP from PD. The mainstay of treatment regimens is levodopa and other dopaminergic drugs; however, due to the increased risk of neuropsychiatric adverse effects, such as emotional dysregulation and impulse control issues, their effectiveness has varied.
The study highlights the need for longitudinal studies to address the lack of knowledge on tau pathology, autoimmune mechanisms, and viral factors in PEP. New methods of diagnosis and treatment are needed to improve outcomes in this uncommon condition. The objective of this research is to increase our understanding of post-encephalitic parkinsonism to develop better management strategies for the condition, given its similarities to idiopathic Parkinson's disease and other developments in neuroimaging and immunology.
References
von Economo K. Die Encephalitis lethargica. Wien Klin Wochenschr. 1917;30:581–585.
Reid AH, McCall S, Henry JM, Taubenberger JK. Experimenting on the past: The enigma of von Economo's encephalitis lethargica. J Neuropathol Exp Neurol. 2001;60(7):663–670. doi:10.1093/jnen/60.7.663
Morassi M, Palmerini F, Nici S, et al. SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients. J Neurol. 2021;268(11):3980-3986. doi:10.1007/s00415-021-10560-3
Ghosh R, Biswas U, Roy D, et al. De novo movement disorders and COVID-19: Exploring the interface. Mov Disord Clin Pract. 2021;8(5):669–680. https://doi.org/10.1002/mdc3.13224
Strobel S, Tappe D, Jellinger K, Riederer P, Monoranu C. Postencephalitic Parkinsonism: unique pathological and clinical features—preliminary data. Cells. 2023;13(18):1511. doi:10.3390/cells13181511
Limphaibool N, Iwanowski P, Holstad MJ, Kobylarek D, Kozubski W. Infectious etiologies of parkinsonism: Pathomechanisms and clinical implications. Front Neurol. 2019;10:6523. https://doi.org/10.3389/fneur.2019.00652
Cadar D, Jellinger KA, Riederer P, Strobel S, Monoranu C, Tappe D. No metagenomic evidence of causative viral pathogens in postencephalitic parkinsonism following encephalitis lethargica. Microorganisms. 2021;9(8):1716. https://doi.org/10.3390/microorganisms9081716
Milburn SE, Hook CV, Steven AJ. Autoimmune encephalitis presenting as dystonia-parkinsonism. Ochsner J. 2022;22(2):110. doi:10.31486/toj.21.0131
Choi JG, Kim N, Ju IG, et al. Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice. Sci Rep. 2018;8(1):1–13. https://doi.org/10.1038/s41598-018-19646-x
Jellinger KA. Neuropathology of postencephalitic parkinsonism. Mov Disord. 2009;24(Suppl 2):S2-S12. doi:10.1002/mds.22632
Vilensky JA, Gilman S, McCall S. A historical analysis of the relationship between encephalitis lethargica and postencephalitic parkinsonism: a complex rather than a direct relationship. Mov Disord. 2010;25(9):1116-1123. doi:10.1002/mds.22990
Vilensky JA, Gilman S, McCall S. Does the historical literature on encephalitis lethargica support a simple (direct) relationship with postencephalitic Parkinsonism? Mov Disord. 2010;25(9):1124-1130. doi:10.1002/mds.22991
Rail D, Scholtz C, Swash M. Post-encephalitic Parkinsonism: current experience. J Neurol Neurosurg Psychiatry. 1981;44(8):670. doi:10.1136/jnnp.44.8.670
Tarazi FI, Sahli ZT, Wolny M, Mousa SA. Emerging therapies for Parkinson’s disease: From bench to bedside. Prog Neurobiol. 2014;119-120:101-117. doi:10.1016/j.pneurobio.2014.06.004
Schwarz ST, Afzal M, Morgan PS, et al. The ‘swallow tail’ appearance of the healthy nigrosome – A new accurate test of Parkinson's disease: A case-control and retrospective cross-sectional MRI study at 3T. PLoS One. 2014;9(4):e93814. https://doi.org/10.1371/journal.pone.0093814
Sacks O. Awakenings. New York: Vintage Books; 1999.
Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol, and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry. 2006;77(3):317-321.
Inzelberg R, et al. Psychobehavioral Effects of Levodopa in Patients with Encephalitis: A Clinical Study. J Neuropsychiatry Clin Neurosci. 2002;14(1):62–69.
LeWitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64–72. https://doi.org/10.1002/mds.26082
Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–376
Ganaraja VH, Kamble N, Netravathi M, Holla VV, Koti N, Kumar Pal DP. Stereotypy with parkinsonism as a rare sequelae of dengue encephalitis: a case report and literature review. Tremor Other Hyperkinet Mov (N Y). 2021;11:22. doi:10.5334/tohm.630